The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 701–800 of 933
Nutrition therapy for diabetes: Implications for decreasing cardiovascular complications
Jialal, I., & Vikram, N. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.008 · Cited by 4
Sheppard, J. P., Palatnic, L., Lakshmanan, S., Drago, T., Bhogal, J., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.102149 · Cited by 3
Polyunsaturated fatty acids in reducing cardiovascular risk
Kołodziejczyk, M., Bułdak, Ł., & Okopień, B. (2021) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2021.0004 · Cited by 3
Current Evidence and Future Directions of Omega-3 Supplementation and Cardiovascular Disease Risk
Dwiputra, B., Santoso, A., Purwowiyoto, B. S., Radi, B., Pandhita, B. A. W., Fatrin, S., & Ambari, A. M. (2023) · International Journal of Angiology · doi:10.1055/s-0043-1777258 · Cited by 3
Chen, H.-C., Tai, C.-J., Huang, J., Kuo, T., Huang, Y.-D., Yen, C., & Lee, M.-C. (2024) · BMC Public Health · doi:10.1186/s12889-024-19512-8 · Cited by 3
Mason, R. P., & Jacob, R. F. (2017) · Springer series in biophysics · doi:10.1007/978-3-319-66601-3_3 · Cited by 3
Kytikovа, O. Y., Novgorodtseva, T. P., Denisenko, Y., Antonyuk, M. V., & Gvozdenko, T. A. (2023) · Bulletin physiology and pathology of respiration · doi:10.36604/1998-5029-2023-87-124-137 · Cited by 3
Diévart, F., Bruckert, É., Aboyans, V., Bekka, S., Boccara, F., Munoz, B. B. B., Emmerich, J., Farnier, M., Gallo, A., Lemesle, G., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.02.004 · Cited by 3
Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease
Maniar, S., & Bittner, V. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_54 · Cited by 3
What's new in nutrition for adults with diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing · doi:10.1097/01.nurse.0000480595.99521.56 · Cited by 3
Tratamiento de la diabetes mellitus (I)
Alcántara, V., & Pérez, A. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.010 · Cited by 3
Damsgaard, C. T., Vuholm, S., Teisen, M. N., Stark, K. D., & Lauritzen, L. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520002822 · Cited by 3
Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients
Clark, D., Puri, R., & Nissen, S. E. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833716 · Cited by 3
The role of icosapent ethyl in cardiovascular risk reduction
Goldenberg, R., CHENG, A. Y. Y., Gilbert, J. D., Lonn, E., Pedersen, S. D., & Verma, S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000873 · Cited by 3
Чешик, И. А., & Михайловна, Ш. Т. (2018) · Health and Ecology Issues · doi:10.51523/2708-6011.2018-15-1-2 · Cited by 3
Singh, N., Dove, E., & Bhatt, D. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00019-4 · Cited by 3
Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici
Marx, N., Federici, M., Schütt, K. S., Müller‐Wieland, D., Ajjan, R., Antunes, M. J., Christodorescu, R., Crawford, C. A., Angelantonio, E. D., Eliasson, B., et al. (2024) · Giornale italiano di cardiologia · doi:10.1714/4162.41558 · Cited by 3
Dwiputra, B., Ambari, A. M., Desandri, D. R., Purwowiyoto, B. S., Radi, B., Pandhita, B. A. W., Fatrin, S., & Santoso, A. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.2.89 · Cited by 3
Hua, R., Lam, C. S., Chu, N. H. S., Yang, A., Chow, E., & Cheung, Y. T. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.11.012 · Cited by 3
Patil, T., Gregory, M., Savona, N., Jarmukli, N. F., & Leonard, C. E. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-024-01417-4 · Cited by 3
Omega-3 Fatty Acids and Health. A Literature Review
Machaj, D., Stawińska-Dudek, J., Józefowicz, W., & Brzoza, M. (2025) · Quality in Sport · doi:10.12775/qs.2025.41.60187 · Cited by 3
Wierzbicki, A. S. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412462042 · Cited by 3
Type 2 Diabetes Mellitus and Dyslipidemia
Cederberg, H., & Laakso, M. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_6 · Cited by 3
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_38 · Cited by 3
Residual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
Drug Therapy of Diabetic Dyslipidemia
Mooradian, A. D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318293b0f9 · Cited by 3
Fish consumption, fish oils, and cardiovascular events: still waiting for definitive evidence
Ridker, P. M. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.143339 · Cited by 3
Editorial commentary: A new era for preventive cardiology
Clarke, S. L. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.007 · Cited by 3
Serhiyenko, V. A. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151151180-84 · Cited by 2
Improving the odds: ezetimibe and cardiovascular disease
Viljoen, A., & Wierzbicki, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12613 · Cited by 2
The importance of omega fatty acids for the prevention of cardiovascular disease
Sargsyan, V. D., & Safaryan, A. S. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212407190 · Cited by 2
Chronic Kidney Disease in Diabetes: Is Fish Oil the Answer?
Gnudi, L. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000543588 · Cited by 2
Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes
Zhuang, P., Liu, X., Jia, W. N., Zheng, W., Wan, X., Chen, W., Gu, J., Li, Y., Lan, X., Li, H., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03082-7 · Cited by 2
Nguyen, N. Q., Ta, K.-N. T., & Chuang, K.-J. (2026) · Cerebrovascular Diseases · doi:10.1159/000550330 · Cited by 2
n-3 and n-6 Fatty Acids Reduce Risk for Cardiovascular Disease
Harris, W. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-22431-2_14 · Cited by 2
Naesgaard, P. A., Grundt, H., Nordøy, A., Staines, H., & Nilsen, D. W. T. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00041 · Cited by 2
Kobara, M., Shiraishi, T., Noda, K., Toba, H., & Nakata, T. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10363-z · Cited by 2
Sheppard, J. P., Lakshmanan, S., Palatnic, L., Dahal, S., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2538404 · Cited by 2
Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases
Kim, C. J. (2013) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2013.2.2.53 · Cited by 2
Update Fettstoffwechselstörungen
Parhofer, K. G. (2013) · Der Internist · doi:10.1007/s00108-013-3335-3 · Cited by 2
Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis
Tatachar, A., Pio, M. Y., Yeung, D., Moss, E., Chow, D. H., Boatright, S. M., Quinones, M. E., Mathew, A., Hulstein, J. L., ADAMS-HUET, B. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.004 · Cited by 2
Hypertriglyceridemia in an outpatient department – Significance as an atherosclerotic risk factor
Scholz, M., Tselmin, S., Fischer, S., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.011 · Cited by 2
Setting the record straight on TIDE: a lost opportunity for patients with diabetes
Punthakee, Z., Bosch, J., & Gerstein, H. C. (2013) · Diabetologia · doi:10.1007/s00125-013-2959-0 · Cited by 2
Limited impact of omega-3 fatty acids in patients with multiple cardiovascular risk factors
Calder, P. C. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101440 · Cited by 2
Update on the Pharmacologic Agents for Dyslipidemia
Lee, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.269 · Cited by 2
Fish and Fish Oil for Cardiovascular Disease in Diabetes
Ward, R. E., & Hintze, K. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802844-5.00020-8 · Cited by 2
Kim, H., Kim, H.-E., Jeong, Y., Yang, S. J., Baik, S. J., Lee, H., Lee, S., Cho, J. H., Choi, I. Y., Yim, H. W., et al. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12423 · Cited by 2
RBC omega-3 predicts risk for death
Harris, W. S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.911 · Cited by 2
Park, H. A., & Kim, S. Y. (2012) · Journal of Korean Medical Association · doi:10.5124/jkma.2012.55.9.889 · Cited by 2
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Плавинский, С. Л., & Barinova, A. N. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10089 · Cited by 2
Effects of Mediterranean Diet on Endothelial Function
Merino, J., KONES, R. J., & Ros, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812348-5.00025-8 · Cited by 2
Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia
Evans, M. C., Stalam, T., & Miller, M. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1013-8 · Cited by 2
The Influence of Unsaturated Fatty Acids for Atherosclerosis in Recent Years
Bando, M., & Bando, H. (2019) · Journal of Obesity and Diabetes · doi:10.33805/2638-812x.110 · Cited by 2
Effects and Issues of Diet Fat on Cardiovascular Metabolism
Nishikawa, Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93261 · Cited by 2
Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis
Susekov, A. V. (2021) · Kardiologiia · doi:10.18087/cardio.2021.6.n1578 · Cited by 2
Dworatzek, P. D. N., Arcudi, K., Gougeon, R., Husein, N., Sievenpiper, J. L., & Williams, S. L. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.048 · Cited by 2
Derosa, G., & Maffioli, P. (2022) · Wiley eBooks · doi:10.1002/9781119746843.ch6 · Cited by 2
Sattar, Y., Suleiman, A. M., Song, D. D., Arshad, J., Prasad, T., Ahmad, B., Osman, H., Halboni, A., Alhusain, R., Ullah, W., et al. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104846 · Cited by 2
RetractedMacronutrients and Nutrition Therapy for Diabetes
MacLeod, J., & Franz, M. J. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580406482.ch02 · Cited by 2
Rosiglitazone and Cardiovascular Outcomes
Gerstein, H. C. (2013) · Circulation · doi:10.1161/circulationaha.113.004652 · Cited by 2
Unsolved Antiatherogenic Mechanism of n-3 Polyunsaturated Fatty Acids
Kawashiri, M., Tada, H., & Yamagishi, M. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1252 · Cited by 2
Abuknesha, N. R., O’Keefe, J. H., Qian, F., Tintle, N. L., Lin, Y., Sun, Y., Qian, H.-Z., Aisen, P. S., Albert, C. M., Aronson, W. J., et al. (2026) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014785 · Cited by 1
“Daily omega-3 doses ranged from 600 to 4000 mg/d, and EPA/DHA was most commonly administered in either an ethyl ester 69,71,73–80,85,87–92,95,97,101 (57”
Sattar, Y., & Alraies, M. C. (2024) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000002215 · Cited by 1
Gnerre, G. E. P., Campanini, M., Fontanella, A., & Nardi, R. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.q.2015.3 · Cited by 1
The Importance of Metabolites in Modulating Insulin Sensitivity
Meiliana, A., Dewi, N. M., & Wijaya, A. (2022) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v14i3.1872 · Cited by 1
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_40 · Cited by 1
Scherer, D., Leite, B. F., Morimoto, M. A., de Oliveira, T. L., Klemz, B. N. D. C., Freitas, R. A. M. S., Pappiani, C., Damasceno, N. R. T., & Pinheiro, M. D. M. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00389-5 · Cited by 1
Mattumpuram, J., Maniya, M. T., Noman, A., Fernandes, C. A. L., Tahir, M. F., Khan, R., Hamza, M., Jaiswal, V., Ali, K., Sathian, B., et al. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70094 · Cited by 1
Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
Sacre, J. W., Lundegard, K., Mohammedi, K., Carstensen, B., Gerstein, H. C., & Shaw, J. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70426 · Cited by 1
Sosnowski, D. K., Hébert, T. E., Dobrev, D., & Nattel, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100129 · Cited by 1
Fish oil supplements in patients with chronic kidney disease
Ferro, C. J., Thomas, M. R., Khattak, S., Chanouzas, D., & Townend, J. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag168 · Cited by 1
Jiang, L., Yuan, P., Chen, H., Fang, X., & Lan, P. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag077 · Cited by 1
Bajnok, L. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29797 · Cited by 1
Basal insulin and n-3 fatty acids—no effect on cardiovascular outcomes
Mitchell, F. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.111 · Cited by 1
Parhofer, K. G. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-1050-6 · Cited by 1
Hypertension and Dyslipidemia in Patients with Pre-Diabetes
Tsimihodimos, V., & Florentin, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00013-2 · Cited by 1
Плавинский, С. Л., & Barinova, A. N. (2017) · Medicina · doi:10.29234/2308-9113-2017-5-4-8-20 · Cited by 1
Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
Kachkovsky, M. A., Vvedenskaya, I. P., Vvedensky, V. Y., Supilnikov, A. A., Ponomareva, J. V., & Milyakova, M. N. (2020) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2020.4.11 · Cited by 1
Die Diabetologische Schwerpunktpraxis – Aufgaben und Versorgungsauftrag
Reuter, H. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_10 · Cited by 1
Diabetes Mellitus and Chronic Kidney Disease (Stages 1–5)
Whitham, D., & Parpia, A. S. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-685-6_8 · Cited by 1
Combination Therapy with Statins
Singh, A., & Davidson, M. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.005 · Cited by 1
Dietary guidelines: Scientific substantiation and public health impact
Murphy, M. (2014) · Nutrition Bulletin · doi:10.1111/nbu.12105 · Cited by 1
Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia
Mehta, N., & deGoma, E. M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0303-7 · Cited by 1
Omega-3-Fettsäuren in der Medizin: Mechanismen, klinische Evidenz und Kontroversen
Reiner, M. F., Stivala, S., Camici, G. G., & Beer, J. H. (2014) · Praxis · doi:10.1024/1661-8157/a001593 · Cited by 1
Omega-3 fatty acids and cardioprotection—IIb or not IIb?
Nikfardjam, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62039-x · Cited by 1
Voeding bij diabetes mellitus type 2
van Wijland, H. (2013) · TvPO · doi:10.1007/s12503-013-0063-z · Cited by 1
Writers, A. M. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0196-y · Cited by 1
Omega-3 for patients with cardiovascular disease.
Turgeon, R. D., Janke, F., & Kolber, M. R. (2012) · PubMed Central · Cited by 1
Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio
Campanini, G. E. M., Nardi, R., & Pinna, G. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.q.2015.4 · Cited by 1
SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE
Филиппов, Е. В., & Yakushin, S. S. (2012) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2012-8-6-788-797 · Cited by 1
(2014) · AAP Grand Rounds · doi:10.1542/gr.31-4-46 · Cited by 1
The Role of Omega-3 Fatty Acids in Dyslipidemias
Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1
Lipoxygenases and Cardiovascular Diseases
Laguna-Fernández, A., Petri, M. H., Thul, S., & Bäck, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27766-0_6 · Cited by 1
Tidlig insulinbehandling ved type 2-diabetes?
Birkeland, K. I. (2012) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.0866 · Cited by 1
Fish, Fish Oil, and Liver Cancer
Zheng, S., & Chen, T. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802844-5.00023-3 · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Effects of Omega-3 Fatty Acids in Myocardial Infarction
Lee, S. Y., Yi, Y. H., & Tak, Y. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_33 · Cited by 1
Omega-3 Fatty Acids and Risk for Cardiovascular Disease
Harris, W. S., & von Schacky, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802844-5.00018-x · Cited by 1
How important are triglycerides as risk factors?
D’Addato, S., Palmisano, S., & Borghi, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000438 · Cited by 1
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
